Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $48.99 USD
Change Today +2.05 / 4.37%
Volume 1.2M
ESPR On Other Exchanges
As of 5:20 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

esperion therapeutics inc (ESPR) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/21/15 - $120.96
52 Week Low
09/9/14 - $15.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

esperion therapeutics inc (ESPR) Related Businessweek News

No Related Businessweek News Found

esperion therapeutics inc (ESPR) Details

Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of oral and low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products include ETC-1002, an oral molecule therapy that is in Phase 2b clinical trials to treat patients with hypercholesterolemia, as well as to lower levels of LDL-cholesterol, and avoid various side effects associated with LDL-cholesterol lowering therapies. The company’s products also comprise 4WF, a synthetic apoA-I therapy for treating patients with acute coronary syndrome has completed Phase 2a clinical studies; and ESP41091, which is in pre-clinical trials for lipid metabolism and body weight reduction. Esperion Therapeutics, Inc. is headquartered in Ann Arbor, Michigan.

21 Employees
Last Reported Date: 03/10/15

esperion therapeutics inc (ESPR) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $450.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $150.0K
Senior Advisor to Chief Executive Officer
Total Annual Compensation: $335.0K
Executive Chairman and Chief Scientific Offic...
Total Annual Compensation: $375.0K
Compensation as of Fiscal Year 2014.

esperion therapeutics inc (ESPR) Key Developments

Esperion Therapeutics Provides Update on The ETC-1002 Development Program Following End-of-Phase 2 Meeting with FDA

Esperion Therapeutics, Inc. provided an update from the ETC-1002 (bempedoic acid) End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) last week. The FDA confirmed that LDL-C remains an acceptable clinical surrogate endpoint for the approval of an LDL-C lowering therapy such as ETC-1002 in patient populations who have a high unmet medical need, including patients with heterozygous familial hypercholesterolemia (HeFH), or clinical atherosclerotic cardiovascular disease (ASCVD), who are already taking maximally tolerated statins yet require additional LDL-C reduction and where there is a positive benefit/risk ratio. Based on feedback from the FDA, approval of ETC-1002 in the HeFH and ASCVD patient populations will not require the completion of a cardiovascular outcomes trial (CVOT). The Company continues to plan and initiate a CVOT prior to NDA filing to pursue broader label indications related to cardiovascular disease risk reduction. Esperion remains on track to initiate the ETC-1002 Phase 3 development program by the end of 2015. The program will support a proposed label indication for the use of ETC-1002, an oral, once-daily LDL-C lowering therapy, as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH), or atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of LDL-C. Approximately nine million patients in the U.S. fall into these two combined categories. The ETC-1002 Phase 3 development program will include clinical studies in patients with ASCVD and HeFH. The study designs will be finalized once minutes from the FDA meeting are received. The Company plans to continue to evaluate ETC-1002 as an add-on to statins, including at all doses.

Esperion Therapeutics, Inc. - Special Call

To discuss ETC-1002 (bempedoic acid) End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA)

Esperion Therapeutics, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Cash Flow Guidance for the Year Ending December 31, 2015

Esperion Therapeutics, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter. the company's loss from operations was $12,462,000 against $9,254,000 a year ago. Net loss was $12,395,000 or $0.55 basic and diluted per share against $9,238,000 or $0.60 basic and diluted per share a year ago. For the six months. the company's loss from operations was $23,887,000 against $17,144,000 a year ago. Net loss was $23,861,000 or $1.11 basic and diluted per share against $17,112,000 or $1.11 basic and diluted per share a year ago. The company expects that the net cash used to fund operating activities in 2015 will be approximately $42 million and that its cash and cash equivalents and investment securities available-for-sale will total approximately $290 million at December 31, 2015. The company expects to incur approximately $12.5 million of noncash expenses during the full year 2015, which primarily consists of stock-based compensation expense. The company expects to end 2015 with approximately $290 million in cash and investment securities.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESPR:US $48.99 USD +2.05

ESPR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ESPR.
View Industry Companies

Industry Analysis


Industry Average

Valuation ESPR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ESPERION THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at